---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-097845"
form_type: "8-K"
ticker: null
cik: "0001567514"
company_name: "Intra-Cellular Therapies, Inc."
filed_at: "2024-04-16T23:59:59+00:00"
generated_at: "2026-06-03T22:14:27.763756+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ITCI launches $500M stock offering; Q1 CAPLYTA sales ~$144.8M; MDD Ph3 positive

## Summary
- Commenced underwritten public offering of $500M common stock; underwriters have 30-day option to purchase additional 15%.
- Preliminary Q1 2024 CAPLYTA net product sales ~$144.8M; cash and equivalents ~$477M as of March 31, 2024.
- Positive Phase 3 topline results for lumateperone 42 mg as adjunctive MDD therapy: MADRS reduction -4.9 pts vs placebo (p<0.0001, ES=0.61).
- Secondary endpoint CGI-S also met (p<0.0001, ES=0.67); safety profile consistent with prior studies.
- Expect to file sNDA for MDD in H2 2024; Study 502 topline results expected late Q2 2024.

## SEC filing metadata
- accession: 0001193125-24-097845
- form_type: 8-K
- cik: 0001567514
- company_name: Intra-Cellular Therapies, Inc.
- filed_at: 2024-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567514/000119312524097845/0001193125-24-097845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567514/000119312524097845/d744972d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-097845
- JSON: https://secwatch.observer/filing/0001193125-24-097845.json
- Plain text: https://secwatch.observer/filing/0001193125-24-097845.txt

## Key facts
- Earnings Releases
  Intra-Cellular Therapies, Inc. reported for the three months ended March 31, 2024 results: revenue $144.8 million.
  - Period: for the three months ended March 31, 2024
  - Revenue: $144.8 million
  - Result: preliminary results
  source text: While we have not finalized our financial results for the first quarter of 2024, we expect to report that, for the three months ended March 31, 2024, our CAPLYTA net product sales were approximately $144.8 million, and as of March 31, 2024, we had cash, cash equivalents, investment securities and restricted cash of approximately $477 million. These amounts are preliminary, unaudited and may change, were prepared by management and are based on the most current information available to management
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567514/000119312524097845/0001193125-24-097845-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.